CLSD - Clearside Biomedical, Inc.
| Previous Close | 1.5500 |
| Open | 1.6200 |
| Bid | 1.57 x 900 |
| Ask | 1.65 x 3100 |
| Day's Range | 1.5700 - 1.7300 |
| 52 Week Range | 0.9900 - 15.3290 |
| Volume | 3,529,015 |
| Avg. Volume | 695,129 |
| Market Cap | 50.598M |
| Beta (3Y Monthly) | -1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings Date | Mar 12, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.86 |
- ACCESSWIRE•23 hours ago
Healthcare Companies Positioned in Major Markets
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Pain relief medicines are a massive market 30 billion doses of which are consumed each year in the US alone. Opioids like codeine and hydrocodone are also ...
- GlobeNewswire•27 days ago
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.
- GlobeNewswire•last month
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Simply Wall St.•2 months ago
Need To Know: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
- GlobeNewswire•2 months ago
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location - anterior, intermediate, posterior or pan. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Teladoc Health and Clearside
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. One was that the company's COO and CFO, Mark Hirschhorn had sold over $700,000 worth of shares last Friday, which amounted to over 81% of his stake in the company.
- Insider Monkey•3 months ago
Major Stock Movers: Inuvo, Clearside Biomedical, Cirrus Logic, and More
It’s Monday and oil futures are relatively stable despite the news that the U.S. is beginning to impose sanctions on Iran again. Among the stocks making substantial waves today include Inuvo Inc. (NYSE:INUV), Clearside Biomedical Inc. (NASDAQ:CLSD), Sysco Corporation (NYSE:SYY), STMicroelectronics N.V. (NYSE:STM), and Cirrus Logic Inc. (NASDAQ:CRUS). Let’s dig deeper into why each stock moved. In the financial world […]
- Simply Wall St.•5 months ago
What Investors Should Know About Clearside Biomedical Inc’s (NASDAQ:CLSD) Financial Strength
Clearside Biomedical Inc (NASDAQ:CLSD) is a small-cap stock with a market capitalization of US$210.7m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
